Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NY › Bay Shore › NPI 1871953109
Lab

Sentra Laboratories INC/

Sentra Laboratories INC/ was paid $510K by Medicaid between Sep 2022 and Jan 2024, across 5 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 57% of everything it billed.

33Billing provider infoSENTRA LABORATORIES INC/
BAY SHORE, NY 11706
33aNPI1871953109assigned 02/29/2016
28Total paid$510K
24GClaims25,502
24DCodes billed5
24AFirst – last monthSep 2022 – Jan 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#61 of 116
Median peer was paid$618K
This provider vs. median0.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
202223,544$410K
20231,928$100K
2024incomplete30$399.40
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 57% 5,751 3,132 $289K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 19% 5,775 3,133 $97K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 16% 750 700 $83K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) 5.1% 4,996 2,775 $26K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 3.0% 8,230 3,375 $15K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLEVY, CHARLES (PRESIDENT)
Same official

Other billing entities under LEVY, CHARLES

Full network →
ProviderLocationPaid
CL Labs INC.Chicago, IL$10.96M
S & T Medical Group LTDHoffman Estates, IL$0.00

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.